An observational study in Pancreatitis, Acute Pancreatitis and Recurrent Pancreatitis, sponsored by Copenhagen University Hospital, Hvidovre. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Copenhagen University Hospital, Hvidovre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pancreatitis, Chronic with a site in Denmark — 2 open to participants now, 3 under way, none of them phase 3. Pancreatitis, Chronic · Denmark.
Among the 14 studies in Pancreatitis, Chronic with a site in Denmark, this one is the only one that started in 2019, is one of 6 observational ones, and was the 9th registered.
266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
Browse Pancreatitis, Chronic studies →2 of the 14 studies in Pancreatitis, Chronic with a site in Denmark are open now. Recruiting first, the newest first:
University of Copenhagen · Sites in Denmark
Ages 18+ · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 300 across 117 observational studies indexed under Pancreatitis, Chronic.
Median enrollment 29 across the 8 interventional studies, 180 across the 6 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Copenhagen University Hospital, Hvidovre is the lead sponsor of 79 studies on the registry; 19 are open to participants now.
Copenhagen University Hospital, Hvidovre has 2 studies filed under Pancreatitis, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Pancreatitis, Chronic with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Observational prospective study evaluating the developement of chronic pancreatitis based on imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative stress.
Chronic pancreatitis (CP) represents the end-stage of a continuous disease process evolving from acute pancreatitis (AP), over recurrent acute pancreatitis (RAP). Due to the irreversible nature of CP, early detection and prevention is key. The study uses state-of-the-art imaging modalities as well as biochemical markers of to evaluate fibrosis progression in patients with pancreatitis.
The included participants have either first time AP, RAP, early CP with preserved pancreatic exocrine and endocrine function or end-stage CP with exocrine insufficiency. Included patients will be followed prospectively for 15 years with advanced MRI and contrast enhanced EUS with elastography, assessment of endocrine and exocrine pancreatic function, biochemical and nutritional assessment, and evaluation of pain processing using quantitative sensory testing. Blood for a biobank will be obtained. The purpose of the biobank is to allow analyses of potential biomarkers for the progression of disease eventually leading to CP.
266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
This study's planned enrollment of 150 is below the median of 300 across 117 observational studies indexed under Pancreatitis, Chronic.
Browse Pancreatitis, Chronic studies →Copenhagen University Hospital, Hvidovre is the lead sponsor of 79 studies on the registry; 19 are open to participants now.
Compared within Pancreatitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with CP, AC pr RAP who are not:
Exclusion Criteria:
The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM. Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP. Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria.
Diagnostic Test: Diagnostic imaging
MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
Also known as: MRI and EUS
Fibrosis progression on endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI)
Progression of fibrosis in the pancreas based on either EUS or MRI
Time frame: 15 years
Lean body mass assessed using bioimpedance
Body composition focusing on lean body mass will be assessed using bioimpedance
Time frame: 15 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2019 (actual). Primary completion is estimated for Jan 2040, 250 months after the start.
Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 250 months is above that.
Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen University Hospital, Hvidovre